CME/CE

CME/CE Courses

Your search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

$Relapsed or Refractory Multiple Myeloma: Integrating Recent Advances Into Your Practice$

R/R Multiple Myeloma: Integrating Advances Into Your Practice | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Provides healthcare providers with an ability to individualize treatment plans for patients with relapsed or refractory multiple myeloma. Exp 10/31/24

Advanced Renal Cell Carcinoma: Making the Most of Immunotherapies and Targeted Agents

Advanced Renal Cell Carcinoma: Immunotherapies and Targeted Agents | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.00 CME CE: Treatment for advanced RCC has evolved rapidly, including next-generation TKIs and immune checkpoint inhibitors. Exp 6/26/24

$BCMA-Directed Therapies: Improving Outcomes of Patients with Relapsed/Refractory Multiple Myeloma$

Improving Relapsed/Refractory Multiple Myeloma Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Provides expert insight and practical strategies on how to incorporate BCMA-targeted therapies into the treatment strategy for relapsed/refractory multiple myeloma. Exp 8/22/24

How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

How I Treat Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME: Expert faculty discuss differing treatment strategies for patients with PNH in this point-counterpoint digital activity highlighting factors underlying selection of C5 or C3 inhibitors. Exp 6/30/24

Exploring the Evolving and Expanding Role of CAR T-Cell Therapies in the Treatment of B-Cell Lymphomas

CAR T-Cell Therapies in B-Cell Lymphomas Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.00 CME CE: Clinicians must comprehensively understand first-, second-, and third-line management of large B-cell lymphomas, including CAR-T therapies. Exp 5/31/24

A Moving Target: Exploring the Use of Maintenance Therapy for Acute Myeloid Leukemia

Maintenance Therapy for Acute Myeloid Leukemia | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.00 CME CE: NCCN guidelines for patients with Acute Myeloid Leukemia that are eligible for maintenance and the importance of treatment goals. Exp 7/21/24

Improving Bladder Cancer Survival by Integrating New Knowledge into Clinical Practice

New Knowledge to Improve Bladder Cancer Survival | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.00 CME CE: Highlights the evolution of care for bladder cancer and provides an expert-led guide to treatment options for first-line therapy and beyond. Exp 5/9/24

Benefitting from Biosimilars — From Theory to Practice

Benefitting from Biosimilars | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.50 CME CE: This 90-minute virtual activity will focus on understanding the best practices for using biosimilars when managing inflammatory conditions. Exp 5/31/24

Improving Patient Outcomes Via Novel Immunotherapy Treatment Options for Large B-Cell Lymphoma

Large B-Cell Lymphoma: Novel Immunotherapy Treatments | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Discusses recently approved agents as well as investigational agents in the treatment of Large B- Cell Lymphoma to provide the best outcomes. Exp 10/12/24

Herpes Zoster Vaccination: New Guidance, New Opportunities to Improve Vaccination Rates

Herpes Zoster: Opportunities to Improve Vaccination Rates | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

1.00 CME CE: Multimedia journey of strategies and protocols for improved HZ vaccination rates to improve disease burden. Exp 5/2/24

More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

Maximizing PARP Inhibitors in Patients with CRPC | myCME

AMA PRA Category 1 Credit(s)^TM

2.00 CME: Experts answer hot-button questions about use of PARP inhibitors in metastatic, castration-resistant prostate cancer; review treatment updates, adverse events. Exp 6/30/24

Managing Metastatic PEComa: Optimizing Care of a Rare and Challenging Soft-tissue Sarcoma

Managing Metastatic Perivascular Endothelial Carcinomas | myCME

AMA PRA Category 1 Credit(s)^TM, IPCE Credit(s)

0.75 CME: PEComas are a group of ultrarare soft-tissue tumors. Learn more about PEComas, how to diagnosis, and treat metastatic disease with a novel mTOR inhibitor. Exp 4/26/25

2024 Psychiatry Update

2024 Psychiatry Update | myCME Live

2024 Psychiatry Update

2024 Psychiatry Update for APPs

2024 Psychiatry Update for APPs | myCME Live

2024 Psychiatry Update for APPs

Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes

Pathogenic Mechanisms of Pulmonary Arterial Hypertension | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.00 CME CE: Current and emerging approaches to pharmacologic therapy for pulmonary arterial hypertension. Exp 6/30/24

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

The Use of SERDs in Managing HR+/ HER2- Breast Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.25 CME: Latest data on next-generation oral SERDs for the treatment of HR+/ HER2- breast cancer. Exp 6/30/24

Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?

Therapies to Optimize Outcomes in Advanced Prostate Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.50 CME CE: Selection and sequence of treatment therapies to optimize management of patients with prostate cancer. Exp 11/30/24

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

Evolving Treatment Paradigms in Breast Cancer Management | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Efficacy and safety findings from recent clinical trials conducted in early and advanced breast cancer settings. Exp 7/31/24

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Multiple Myeloma from the Summer Meetings

Therapies Under Evaluation for Multiple Myeloma Management | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.50 CME CE: Optimizing the use of second-line therapies including lurbinectedin and topotecan for extensive-stage SCLC; patient cases focusing on individualizing care. Exp 6/28/24

Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA

Targeting FGFR2 and Pan-FGFR in CCA | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.00 CME CE: Optimizing the use of FGFR inhibitors in patients with intrahepatic cholangiocarcinoma. Exp 6/28/24